Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBT-NM108 in Multiple Sclerosis
NCT04574024Phase 2Completed
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NBT-NM108 in relapsing-remitting multiple sclerosis (RRMS). Primary endpoints: Serum Tumor Necrosis Factor-alpha Levels at 12 weeks, Abundance of Anaerostipes bacteria at 12 weeks and 1 more. Started Mar 2022; status: completed.
02
Drugs
NBT-NM108
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04574024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574024.